{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:52Z","timestamp":1791304312271,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00923-1","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:34:23Z","timestamp":1775072063000},"page":"1293-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg"],"prefix":"10.1007","volume":"15","author":[{"given":"Flora","family":"D\u2019Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicasio","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Erra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tuccillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-1655","authenticated-orcid":false,"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"26","key":"923_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med [Internet]. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med [Internet]."},{"key":"923_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000212371","volume-title":"Immune-mediated neuromuscular diseases","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN. Myasthenia Gravis with anti-acetylcholine receptor antibodies. In: Immune-mediated neuromuscular diseases. Basel: KARGER; 2009. p. 94\u2013108."},{"key":"923_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"923_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho S, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8\u201319.","journal-title":"Muscle Nerve"},{"issue":"4","key":"923_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"key":"923_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C, DiMuzio A, Habetswallner F, Iani C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci. 2019;40:1111\u201324.","journal-title":"Neurol Sci"},{"key":"923_CR7","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;2012(12).","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"923_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jocn.2021.06.021","volume":"90","author":"W Chun","year":"2021","unstructured":"Chun W, Kim Y, Park SH, Choi SJ. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders. J Clin Neurosci. 2021;90:311\u20136.","journal-title":"J Clin Neurosci"},{"issue":"12","key":"923_CR9","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"issue":"23","key":"923_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0000000000007605","volume":"92","author":"AC Guidon","year":"2019","unstructured":"Guidon AC, Juel VC. Efgartigimod: a novel antibody depletion therapy in myasthenia gravis. Neurology [Internet]. 2019;92(23):1079\u201380.","journal-title":"Neurology [Internet]."},{"key":"923_CR11","doi-asserted-by":"crossref","unstructured":"Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, et al. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021;430.","DOI":"10.1016\/j.jns.2021.118074"},{"issue":"10","key":"923_CR12","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig. 2018;128(10):4372\u201386.","journal-title":"J Clin Investig"},{"issue":"7","key":"923_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"923_CR14","doi-asserted-by":"crossref","unstructured":"Di Stefano V, Iacono S, Militello M, Leone O, Rispoli MG, Ferri L, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci [Internet]. 2024.","DOI":"10.1007\/s10072-024-07368-0"},{"key":"923_CR15","doi-asserted-by":"crossref","unstructured":"Sivadasan A, Bril V. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy [Internet]. 2023.","DOI":"10.2217\/imt-2022-0298"},{"issue":"7","key":"923_CR16","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jaip.2022.04.003","volume":"10","author":"JG Demain","year":"2022","unstructured":"Demain JG, Bonilla FA. Efgartigimod: potential impact on IVIG therapy. J Allergy Clin Immunol Pract. 2022;10(7):1930.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"923_CR17","doi-asserted-by":"crossref","unstructured":"Ma J, Zhang H, Zhao J, Su M, Feng Y, Yuan X, et al. Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep [Internet]. 2024;14(1).","DOI":"10.1038\/s41598-024-79918-7"},{"key":"923_CR18","doi-asserted-by":"crossref","unstructured":"Zhang C, Li X, Deng Y, Luo H, Wang S, Yan X, et al. The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients. Clin Immunol [Internet]. 2025;274.","DOI":"10.1016\/j.clim.2025.110457"},{"key":"923_CR19","doi-asserted-by":"crossref","unstructured":"Watanabe K, Ohashi S, Watanabe T, Kakinuma Y, Kinno R. Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol [Internet]. 2024;15.","DOI":"10.3389\/fneur.2024.1321058"},{"issue":"5","key":"923_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jca.22002","volume":"37","author":"MH Tran","year":"2022","unstructured":"Tran MH. \u201cPlasma exchange in a bottle\u201d: An overview of efgartigimod for apheresis practitioners. J Clin Apher [Internet]. 2022;37(5):512\u20135.","journal-title":"J Clin Apher [Internet]."},{"issue":"11","key":"923_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.tips.2018.08.004","volume":"39","author":"J Bayry","year":"2018","unstructured":"Bayry J, Kaveri SV. Kill \u2019Em All: efgartigimod immunotherapy for autoimmune diseases. Trends Pharmacol Sci [Internet]. 2018;39(11):919\u201322.","journal-title":"Trends Pharmacol Sci [Internet]."},{"issue":"3","key":"923_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"923_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"key":"923_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","author":"YA Heo","year":"2023","unstructured":"Heo YA. Efgartigimod Alfa in Generalised Myasthenia Gravis: a profile of its use. CNS Drugs. 2023. https:\/\/doi.org\/10.1007\/s40263-023-01000-z.","journal-title":"CNS Drugs"},{"issue":"3","key":"923_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146(3):467\u201378.","journal-title":"J Allergy Clin Immunol"},{"key":"923_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110457","volume":"274","author":"C Zhang","year":"2025","unstructured":"Zhang C, Li X, Deng Y, Luo H, Wang S, Yan X, et al. The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients. Clin Immunol. 2025;274:110457.","journal-title":"Clin Immunol"},{"key":"923_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-023-11970-1","volume":"1","author":"V Di Stefano","year":"2023","unstructured":"Di Stefano V, Alonge P, Rini N, Militello M, Lupica A, Torrente A, et al. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol [Internet]. 2023;1:1\u20139. https:\/\/doi.org\/10.1007\/s00415-023-11970-1.","journal-title":"J Neurol [Internet]."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00923-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:08:18Z","timestamp":1778681298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00923-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that Flora D\u2019Amico, Sofia Campo, Nicasio Rini, Claudia Vinciguerra, Liliana Bevilacqua, Carmen Erra, Paolo Barone, Francesco Tuccillo, Francesco Habetswallner, Filippo Brighina and Vincenzo Di Stefano have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the appropriate Ethics Committee \u201cPalermo I\u201d protocol code 11\/2022, approved on 12 December 2022, and it was conducted in conformity with the Declaration of Helsinki principles. All participating centers adhered to the study protocol.\u00a0Patient informed consent was obtained and signed for the study and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}